Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date
Hong Kong: These 22 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "Hong Kong: These 22 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Hong Kong?
Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Hong Kong Patent 1,214,513
SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.
See drug price trends for SIRTURO.
The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.
When can LETAIRIS (ambrisentan) generic drug versions launch in Hong Kong?
Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Hong Kong Patent 1,218,393
Patent Title: 用於治療肺高壓的複合物 (COMPOSITION FOR TREATING A PULMONARY HYPERTENSION)
LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LETAIRIS
See drug price trends for LETAIRIS.
The generic ingredient in LETAIRIS is ambrisentan. Additional details are available on the ambrisentan profile page.
When can VYKAT XR (diazoxide choline) generic drug versions launch in Hong Kong?
Generic name: diazoxide choline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: Hong Kong Patent 1,117,078
Patent Title: SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF
VYKAT XR is a drug marketed by Soleno. There are six patents protecting this drug. There has been litigation on patents covering VYKAT XR
The generic ingredient in VYKAT XR is diazoxide choline. Additional details are available on the diazoxide choline profile page.
When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Hong Kong?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Hong Kong Patent 1,142,818
PANCREAZE is a drug marketed by
See drug price trends for PANCREAZE.
The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Hong Kong?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Hong Kong Patent 1,142,818
ZENPEP is a drug marketed by
See drug price trends for ZENPEP.
The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can VANFLYTA (quizartinib dihydrochloride) generic drug versions launch in Hong Kong?
Generic name: quizartinib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2027
Generic Entry Controlled by: Hong Kong Patent 1,131,141
VANFLYTA is a drug marketed by Daiichi Sankyo Inc. There are eleven patents protecting this drug.
See drug price trends for VANFLYTA.
The generic ingredient in VANFLYTA is quizartinib dihydrochloride. Additional details are available on the quizartinib dihydrochloride profile page.
When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in Hong Kong?
Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: Hong Kong Patent 1,141,349

See drug price trends for QVAR REDIHALER.
The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. Additional details are available on the beclomethasone dipropionate profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch in Hong Kong?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Hong Kong Patent 1,136,968
PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.
When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Hong Kong?
Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Hong Kong Patent 1,140,473

See drug price trends for VRAYLAR.
The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.
When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Hong Kong?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Hong Kong Patent 1,141,737
TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.
See drug price trends for TRELSTAR.
The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.
When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Hong Kong?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Hong Kong Patent 1,141,737
TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.
The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch in Hong Kong?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Hong Kong Patent 1,165,807
Patent Title: 合成的胆汁酸製備方法 (SYNTHETIC BILE ACID PREPARATION)
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch in Hong Kong?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Hong Kong Patent 1,223,372
Patent Title: 脫氧膽酸 的合成 (SYNTHESIS OF DEOXYCHOLIC ACID (DCA) (DCA))
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.
When can CARDAMYST (etripamil) generic drug versions launch in Hong Kong?
Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: Hong Kong Patent 1,140,913
Patent Title: 短效苯烷基胺鈣通道阻斷劑及其應用 (SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF)

See drug price trends for CARDAMYST.
The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.
When can BYFAVO (remimazolam besylate) generic drug versions launch in Hong Kong?
Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Hong Kong Patent 1,137,739
Patent Title: 短效苯並二氮雜噁鹽及其多晶型 (SHORT-ACTING BENZODIAZEPINE SALTS AND THEIR POLYMORPHIC FORMS)
BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO
See drug price trends for BYFAVO.
The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.
When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Hong Kong?
Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Hong Kong Patent 1,145,265
Patent Title: PYRIDAZINONE DERIVATES
TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO
See drug price trends for TEPMETKO.
The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.
When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in Hong Kong?
Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: Hong Kong Patent 1,126,486
Patent Title: 丙型肝炎病毒 抑制劑 (HEPATITIS C VIRUS INHIBITORS (HCV))

See drug price trends for DAKLINZA.
The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.
When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in Hong Kong?
Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: Hong Kong Patent 1,212,588
LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.
See drug price trends for LOCAMETZ.
The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.
When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Hong Kong?
Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Hong Kong Patent 1,207,298
Patent Title: 藥物組合物 (PHARMACEUTICAL COMPOSITIONS)

See drug price trends for VELPHORO.
The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in Hong Kong?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Hong Kong Patent 1,134,290
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.
When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Hong Kong?
Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Hong Kong Patent 1,160,843

See drug price trends for DUZALLO.
The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.
When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Hong Kong?
Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Hong Kong Patent 1,180,337

See drug price trends for DUZALLO.
The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.
When can ZURAMPIC (lesinurad) generic drug versions launch in Hong Kong?
Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Hong Kong Patent 1,160,843
ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC
See drug price trends for ZURAMPIC.
The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.
When can ZURAMPIC (lesinurad) generic drug versions launch in Hong Kong?
Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Hong Kong Patent 1,180,337
ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC
See drug price trends for ZURAMPIC.
The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.
When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Hong Kong?
Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Hong Kong Patent 1,223,850

See drug price trends for INVEGA SUSTENNA.
The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.
More… ↓
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
